CMS will now offer payers enticements to increase patient med adherence under the existing MTM model. The Part D effort is specifically focused on stand-alone Part D plans.
In September 2015, the Centers for Medicare and Medicaid Services (CMS) expanded its Medicare Part D program to include medication adherence for beneficiaries of its Medicare Part D plans.
Ned MilenkovichAlthough “medication therapy management” (MTM) is a cognitive intervention of longstanding in pharmacy practice, CMS will now offer payers enticements to increase patient adherence to their medications under the existing MTM model. The Part D effort is specifically focused on stand-alone Part D plans.
See also: HHS releases 340B Proposed Guidance
Substantial improvement
The new Part D MTM model will address whether providing Part D sponsors with additional payment incentives and regulatory flexibilities will sharpen the MTM program, leading to improved therapeutic outcomes while reducing net Medicare expenditures. Stand-alone basic Part D plans can benefit through implemention of innovative strategies to optimize medication use, improve coordination of care, and strengthen system linkages.
See also: Washington state requires pharmacies to stock Plan B
Tailored MTM services will be available for participating Part D plans. Factors such as the enrollee’s level of medication-related risk and current barriers to improvement will be used to determine the appropriate services to provide.
This approach is a substantial improvement over the current model, which provides uniform service offerings to all Part D enrollees who meet the program’s criteria. The criteria, which are based on numbers of medications, chronic conditions, and expected annual prescription drug costs, do not include a variable to account for the enrollee’s specific needs or risk factors.
The new MTM model comes as stand-alone Part D plan premiums are projected to increase, while the number of plans will decrease.
Big changes
Avalere Health, a healthcare consulting firm based in Washington D.C., has released the following figures:
Ten of the most popular Part D plans, representing more than 80% of Part D plan enrollment, will have an average premium increase of 8% in 2016. This will increase many beneficiaries’ premiums to more than $40 a month, a first since the program’s inception in 2006. The number of plans is dropping 13.5%, from 1,001 currently to 886 next year.
“Medicare beneficiaries should carefully review their prescription drug plan options in 2016 to make sure they choose a plan that is right for them,” Colin Shannon, senior manager at Avalere Health, said in a statement. “With many plans taking large premium increases in 2016, those beneficiaries who choose not to change plans will likely pay more in premiums than if they look for lower-cost options.”
Nonadherence grows
Stakeholders hope that the new model will be a beacon for change, as medication nonadherence has been steadily increasing. For instance, a 2014 Health Affairs analysis found that nonadherence increased from 14.4% in 2009 to 17% in 2011 among elderly beneficiaries with four or more chronic conditions.
Similarly, among the sickest elderly, the percentage that forwent basic needs in order to purchase medications went from 6.8% in 2009 to 10.2% in 2011.
The new MTM model will begin its five-year pilot in five regions: Arizona, Florida, Louisiana, Virginia, and a larger region that includes Iowa, Minnesota, Montana, Nebraska, North Dakota, South Dakota, and Wyoming.
Officials at CMS call the changes extremely positive. “As part of our approach to building a healthcare delivery system that results in better care, smarter spending, and healthier people, CMS will test changes to the Part D program to give prescription drug plans stronger incentives and flexibility to improve prescription drug safety and efficacy,” said Dr. Patrick Conway, CMS deputy administrator for innovation and quality, in a statement about the model.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.